Tempest Therapeutics registers 2.4M shares for selling stockholders upon warrant exercise at $1.73

Filed July 8, 2026 · ~2 min read

Key Changes

• high

  This is a secondary offering: up to 2,426,897 shares issuable upon warrant exercise are registered for resale by selling stockholders. Tempest receives no proceeds from these share sales; all proceeds go to the selling stockholders.

  Use of Proceeds verify on EDGAR →
• high

  Tempest may receive up to $4.23 million if all warrants are exercised for cash. The New Warrants have a $1.73 exercise price and expire May 29, 2028, but require stockholder approval before becoming exercisable per Nasdaq rules.

  The Offering verify on EDGAR →
• high

  The warrants stem from a May 2026 inducement transaction where Tempest induced a holder to exercise 1,172,414 existing warrants at a reduced price of $1.73 (down from $3.50) by issuing replacement warrants at the same $1.73 price, generating $2.0 million in immediate proceeds.

  Prospectus Summary verify on EDGAR →